RT Journal Article
T1 Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
A1 Garassino, Marina Chiara
A1 Cho, Byoung-Chul
A1 Kim, Joo-Hang
A1 Mazières, Julien
A1 Vansteenkiste, Johan
A1 Lena, Hervé
A1 Jaime, Jesus Corral
A1 Gray, Jhanelle E
A1 Powderly, John
A1 Chouaid, Christos
A1 Bidoli, Paolo
A1 Wheatley-Price, Paul
A1 Park, Keunchil
A1 Soo, Ross A
A1 Poole, Lynne
A1 Wadsworth, Catherine
A1 Dennis, Phillip A
A1 Rizvi, Naiyer A
K1 ATLANTIC
K1 Durvalumab
K1 NSCLC
K1 Overall survival
K1 Safety
AB In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS and updated safety data. Patients with advanced NSCLC with disease progression following ≥2 previous systemic regimens received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among patients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). Secondary endpoints included OS and safety. 444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR-/ALK-), and 68 in Cohort 3 (EGFR-/ALK-; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3-24.5) in patients with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6-13.6) in patients with EGFR-/ALK- NSCLC with TC ≥ 25 %, and 13.2 months (5.9-not reached) in patients with EGFR-/ALK- NSCLC with TC ≥ 90 %. Median (95 % CI) OS was slightly shorter in patients with TC  After additional follow-up, final OS data remain encouraging across all cohorts, further supporting the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with EGFR+/ALK+ tumours. There were no new safety signals.
YR 2020
FD 2020-06-30
LK http://hdl.handle.net/10668/15981
UL http://hdl.handle.net/10668/15981
LA en
DS RISalud
RD Apr 11, 2025